2021-2022 Regular SessionNew York Legislature

A07245

Legislative Summary

Relates to preserving access to affordable drugs; provides that an agreement resolving or settling, on a final or interim basis, a patent infringement claim, in connection with the sale of a pharmaceutical product, shall be presumed to have anticompetitive effects if a nonreference drug filer receives anything of value from another company asserting patent infringement and if the nonreference drug filer agrees to limit or forego research, development, manufacturing, marketing, or sales of the nonreference drug filer's product for any period of time.

Bill History

4/29/2021
referred to health
Assembly
1/5/2022
referred to health
Assembly
5/23/2022
amend and recommit to health
Assembly
5/23/2022
print number 7245a
Assembly